Erythromycin

Phase 2

GENMAB A/S (GNMSF)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jul '27

GNMSFPhase 2$21.5B

Erythromycin Phase 2 Est. Readout

Erythromycin• High Grade Epithelial Ovarian Cancer952

Jul 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in High Grade Epithelial Ovarian Cancer

View Full Landscape

Drug Information

Target Indication

High Grade Epithelial Ovarian Cancer

Clinical Trial

NCT05579366

Last updated: 10/8/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

GNMSF

GENMAB A/S

Biotechnology•North America•NASDAQ

Related Pipeline

ZalutumumabPhase 3

Head and Neck Neoplasms

EpcoritamabPhase 3

DLBCL

Rina-SPhase 3

Non-small Cell Lung Cancer (NSCLC)

Investigator's Choice ChemotherapyPhase 3

Diffuse Large B-cell Lymphoma

PetosemtamabPhase 3

Left-sided Colorectal Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts